CD8A and neoplasm: Both in vivo and in vitro experiments showed that APS combined with CAR-T significantly inhibited tumour growth in Huh7 and HepG2 models and improved the persistence and functionality of CD8+ CAR-T cells, offering a new strategy for liver cancer immunotherapy with the appropriate concentration of 800 μg/mL [63].